Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Assessing the tissue penetration and clearance of therapeutic oligonucleotides

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Assessing the tissue penetration and clearance of therapeutic oligonucleotides

Pharmacokinetics of Therapeutic Oligonucleotides: Tissue Penetration and Clearance

CELL & GENE | RNA | BIOLOGICS

The technical approach for assessing the pharmacokinetics (PK) of therapeutic oligonucleotides centers on tissue penetration, biodistribution, and clearance. We detail the analytical methodologies and strategic considerations for characterizing how these complex biologics behave in vivo, which is fundamental for establishing a clear dose-response relationship and safety profile ahead of clinical entry.

    What are the primary challenges in quantifying oligonucleotide distribution in tissues?

    A: The main challenges include achieving sufficient assay sensitivity to detect low concentrations in non-target tissues, distinguishing the parent oligonucleotide from its metabolites, and managing potential matrix effects from complex biological samples like tissue homogenates.

    Which analytical platforms are best suited for oligonucleotide PK studies?

    A: A hybrid approach is often optimal. Ligand-binding assays (LBA) like ELISA or Meso Scale Discovery (MSD) offer high throughput for plasma analysis. For tissue quantification and metabolite identification, liquid chromatography-mass spectrometry (LC-MS/MS) provides superior specificity and resolution.

    How does the delivery vehicle impact the PK profile of an oligonucleotide therapeutic?

    A: The delivery system dictates the biodistribution profile. As demonstrated in recent literature (PMID: 39354147), engineered lipid nanoparticles (LNPs) can be designed to augment intracellular processing and achieve tissue-specific delivery, fundamentally altering the absorption, distribution, metabolism, and excretion (ADME) properties of the oligonucleotide payload.

    What is the typical sample matrix required for a comprehensive tissue penetration study?

    A: A full PK profile requires analysis of plasma or serum for systemic exposure, alongside tissue homogenates from key organs of interest (e.g., liver, kidney, spleen, lung) and potential sites of toxicity. Urine and feces may also be collected for excretion analysis.

Characterizing Oligonucleotide ADME Profiles

A therapeutic oligonucleotide’s efficacy and safety are directly linked to its in vivo journey. Understanding its absorption, distribution to target and non-target tissues, metabolism, and eventual clearance is a foundational component of any successful Investigational New Drug (IND) application. Our programs are designed to provide a precise characterization of this PK profile, generating the decision-driving data needed for lead candidate selection and dose optimization.

Our approach integrates multiple analytical techniques to build a complete picture:

  • Systemic Exposure: Quantifying the concentration of the therapeutic in circulation over time to determine key parameters like Cmax, Tmax, and area under the curve (AUC).

  • Tissue Biodistribution: Assessing the extent and rate of distribution into target tissues to confirm engagement and into non-target tissues to evaluate potential safety liabilities.

  • Metabolite Profiling: Identifying and quantifying major metabolites to understand the stability and degradation pathways of the parent compound.

A digital rendering of a DNA double helix on a dark blue background with floating particles.

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

The Impact of Advanced Delivery Systems

The delivery vehicle is as important as the oligonucleotide payload itself. Novel delivery platforms are being engineered to overcome biological barriers and improve therapeutic index. Innovations in lipid nanoparticle (LNP) formulation, for example, now allow for designs that augment intracellular processing and enhance tissue-specific delivery. These advancements directly influence the PK profile, enabling more precise targeting and potentially reducing the required therapeutic dose. Our studies are designed to characterize these sophisticated delivery systems, providing clear data on how formulation changes translate to in vivo performance.

At our >100,000 sq ft GxP-compliant facility, we leverage this deep understanding to support programs from discovery through IND submission. This focused expertise contributes to our standard 18-24 month IND timeline. Since the Franklin Biolabs brand launched in 2024, programs managed by our core scientific leadership have maintained a 100% IND success rate, a record established since 2019.

Animal Welfare and Regulatory Compliance

All in vivo studies are conducted in strict accordance with the highest ethical standards. Our animal welfare program, accredited by AAALAC and regulated by the USDA, is built upon the “3Rs” principles: Replacement, Reduction, and Refinement. This commitment ensures both data integrity and the ethical treatment of all research subjects.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities